CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH The TKI could offer hope against resistance mutations
In a significant advancement for the treatment of ROS1 fusion–positive non–small-cell lung cancer (NSCLC), the study focuses on the efficacy and safety of repotrectinib, a next-generation ROS1 tyrosine kinase inhibitor (TKI). This research holds substantial promise, particularly for patients exhibiting resistance mutations or requiring enhanced intracranial efficacy.
Study Design:
- Participants: Advanced solid tumor patients, including those with ROS1 fusion–positive NSCLC.
- Trial Phases: Registrational phase 1–2 trial.
- Dosage: Recommended phase 2 dose of repotrectinib was 160 mg daily for 14 days, then 160 mg twice daily.
Key Findings:
- Efficacy in Naïve Patients: 79% response rate in patients not previously treated with a ROS1 TKI.
- Duration of Response: Median duration was 34.1 months in naïve patients and 14.8 months in previously treated patients.
- Progression-Free Survival: Median of 35.7 months in naïve patients, and 9.0 months in previously treated patients.
- Efficacy in Mutation Cases: 59% response in patients with the ROS1 G2032R mutation.
- Adverse Events: Most common were dizziness, dysgeusia, and paresthesia; low discontinuation rate due to adverse events.
HCN Medical Memo
Repotrectinib demonstrated sustained effectiveness in treating ROS1 fusion-positive NSCLC in patients, regardless of their previous exposure to ROS1 TKIs. The treatment was generally well-tolerated, with most adverse events being of low severity, suggesting its suitability for long-term use in managing this condition.
More on Lung Cancer
